JP2018505144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505144A5 JP2018505144A5 JP2017532799A JP2017532799A JP2018505144A5 JP 2018505144 A5 JP2018505144 A5 JP 2018505144A5 JP 2017532799 A JP2017532799 A JP 2017532799A JP 2017532799 A JP2017532799 A JP 2017532799A JP 2018505144 A5 JP2018505144 A5 JP 2018505144A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- cxcl12
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 64
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 36
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 22
- 229940127121 immunoconjugate Drugs 0.000 claims description 21
- 238000012217 deletion Methods 0.000 claims description 20
- 230000037430 deletion Effects 0.000 claims description 20
- 238000003780 insertion Methods 0.000 claims description 20
- 230000037431 insertion Effects 0.000 claims description 20
- 238000006467 substitution reaction Methods 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 17
- 230000001404 mediated effect Effects 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- -1 AAL881 Chemical compound 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 230000033115 angiogenesis Effects 0.000 claims description 9
- 230000004071 biological effect Effects 0.000 claims description 8
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 6
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 230000012292 cell migration Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 102000043525 human CXCL12 Human genes 0.000 claims description 4
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 238000004393 prognosis Methods 0.000 claims description 3
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 3
- VPBYZLCHOKSGRX-UHFFFAOYSA-N 1-[2-chloro-4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-propylurea Chemical compound C1=C(Cl)C(NC(=O)NCCC)=CC=C1OC1=NC=NC2=CC(OC)=C(OC)C=C12 VPBYZLCHOKSGRX-UHFFFAOYSA-N 0.000 claims description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
- BLAFVGLBBOPRLP-UHFFFAOYSA-N 2-(pyridin-4-ylmethylamino)-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound FC(F)(F)C1=CC=CC(NC(=O)C=2C(=CC=CC=2)NCC=2C=CN=CC=2)=C1 BLAFVGLBBOPRLP-UHFFFAOYSA-N 0.000 claims description 2
- FGTCROZDHDSNIO-UHFFFAOYSA-N 3-(4-quinolinylmethylamino)-N-[4-(trifluoromethoxy)phenyl]-2-thiophenecarboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)C1=C(NCC=2C3=CC=CC=C3N=CC=2)C=CS1 FGTCROZDHDSNIO-UHFFFAOYSA-N 0.000 claims description 2
- OOQXPATWSOGSAV-UHFFFAOYSA-N 6-(5-methyl-1,3,4-oxadiazol-2-yl)-n-(2-methyl-1h-pyrrolo[2,3-b]pyridin-5-yl)-5-propan-2-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine Chemical compound C=1N2N=CN=C(NC=3C=C4C=C(C)NC4=NC=3)C2=C(C(C)C)C=1C1=NN=C(C)O1 OOQXPATWSOGSAV-UHFFFAOYSA-N 0.000 claims description 2
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 108010079709 Angiostatins Proteins 0.000 claims description 2
- 108090000644 Angiozyme Proteins 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 201000000512 Intraocular Lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical group C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims description 2
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000010115 WHIM syndrome Diseases 0.000 claims description 2
- 229960002833 aflibercept Drugs 0.000 claims description 2
- 108010081667 aflibercept Proteins 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims description 2
- 238000009175 antibody therapy Methods 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 2
- 229940120638 avastin Drugs 0.000 claims description 2
- 229960003005 axitinib Drugs 0.000 claims description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- LTEJRLHKIYCEOX-OCCSQVGLSA-N brivanib alaninate Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@@H](C)OC(=O)[C@H](C)N)=C1 LTEJRLHKIYCEOX-OCCSQVGLSA-N 0.000 claims description 2
- 229950005993 brivanib alaninate Drugs 0.000 claims description 2
- 230000004712 cancer cell adhesion Effects 0.000 claims description 2
- 230000009702 cancer cell proliferation Effects 0.000 claims description 2
- 229940056434 caprelsa Drugs 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229940082789 erbitux Drugs 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 229950003968 motesanib Drugs 0.000 claims description 2
- YBTGTVGEKMZEQX-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(triazol-1-yl)ethoxy]quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCN3N=NC=C3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F YBTGTVGEKMZEQX-UHFFFAOYSA-N 0.000 claims description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims description 2
- CUPLTRAPYIXFAX-UHFFFAOYSA-N n-cyclopropyl-2,4-difluoro-5-[[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]methylamino]benzamide Chemical compound FC1=CC(F)=C(C(=O)NC2CC2)C=C1NCC(S1)=CN=C1NC1=CC=CC=N1 CUPLTRAPYIXFAX-UHFFFAOYSA-N 0.000 claims description 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960000639 pazopanib Drugs 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 229950001248 squalamine Drugs 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 229940034785 sutent Drugs 0.000 claims description 2
- 229960003433 thalidomide Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 229950000578 vatalanib Drugs 0.000 claims description 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 2
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims 2
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 229950002216 linifanib Drugs 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 229960000940 tivozanib Drugs 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422502 | 2014-12-17 | ||
| GB1422502.3 | 2014-12-17 | ||
| PCT/EP2015/079384 WO2016096640A2 (en) | 2014-12-17 | 2015-12-11 | Anti-cxcl12 antibody molecules and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018505144A JP2018505144A (ja) | 2018-02-22 |
| JP2018505144A5 true JP2018505144A5 (enExample) | 2019-01-31 |
Family
ID=54848570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532799A Ceased JP2018505144A (ja) | 2014-12-17 | 2015-12-11 | 抗ｃｘｃｌ１２抗体分子およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10647766B2 (enExample) |
| EP (1) | EP3233112A2 (enExample) |
| JP (1) | JP2018505144A (enExample) |
| CN (1) | CN107207590A (enExample) |
| AU (1) | AU2015366512A1 (enExample) |
| CA (1) | CA2970857A1 (enExample) |
| IL (1) | IL252932A0 (enExample) |
| WO (1) | WO2016096640A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7743633B2 (ja) * | 2021-12-27 | 2025-09-24 | エピ バイオテック カンパニー リミテッド | Ｃｘｃｌ１２に対する抗体及びそれを含む脱毛治療用組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1871807B1 (en) * | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
| WO2008009437A2 (en) * | 2006-07-18 | 2008-01-24 | Noxxon Pharma Ag | Sdf-i binding nucleic acids |
| ES2396220T3 (es) * | 2006-08-11 | 2013-02-20 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1) |
| WO2008021263A2 (en) | 2006-08-11 | 2008-02-21 | Medarex, Inc. | Methods of indentifying antibodies that bind oligomeric forms of chemokines and uses thereof |
| CA2672944A1 (en) * | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders |
| GB201002238D0 (en) * | 2010-02-10 | 2010-03-31 | Affitech As | Antibodies |
| AR084141A1 (es) * | 2010-11-19 | 2013-04-24 | Imai Toshio | Anticuerpos neutralizadores anti-ccl20 |
-
2015
- 2015-12-11 WO PCT/EP2015/079384 patent/WO2016096640A2/en not_active Ceased
- 2015-12-11 CN CN201580073656.9A patent/CN107207590A/zh active Pending
- 2015-12-11 AU AU2015366512A patent/AU2015366512A1/en not_active Abandoned
- 2015-12-11 EP EP15808213.1A patent/EP3233112A2/en not_active Withdrawn
- 2015-12-11 JP JP2017532799A patent/JP2018505144A/ja not_active Ceased
- 2015-12-11 CA CA2970857A patent/CA2970857A1/en not_active Abandoned
- 2015-12-11 US US15/535,976 patent/US10647766B2/en not_active Expired - Fee Related
-
2017
- 2017-06-15 IL IL252932A patent/IL252932A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2991628C (en) | A novel approach for treatment of cancer using immunomodulation | |
| TWI457346B (zh) | 包含專一性辨識ｃｄ３８之抗體及環磷醯胺（ｃｙｃｌｏｐｈｏｓｐｈａｍｉｄｅ）之抗腫瘤組合 | |
| TWI457124B (zh) | 包含專一性辨識ｃｄ３８之抗體及長春新鹼（ｖｉｎｃｒｉｓｔｉｎｅ）之抗腫瘤組合 | |
| CN100410275C (zh) | 新的抗igf-ir抗体及其应用 | |
| AU2010247464B2 (en) | Humanized AXL antibodies | |
| CN103347898B (zh) | 包括与肿瘤相关抗原结合抗体的联合治疗 | |
| KR102757960B1 (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| IL263466B1 (en) | Anti-cd3 antibodies and methods of using them | |
| CN111363041A (zh) | 新型抗-pd-l1抗体 | |
| JP2015509947A5 (enExample) | ||
| JP2011521647A (ja) | 抗ｆｌｔ３抗体 | |
| TW201307392A (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| KR20180088445A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| JP2022536602A (ja) | 濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法 | |
| CN112043826A (zh) | 包含抗cd38抗体和卡非佐米的组合物 | |
| JP2020507339A (ja) | 抗ｇ−ｃｓｆ抗体及びその使用 | |
| JP2024054123A (ja) | 癌の治療のための配合剤 | |
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| CN116744976A (zh) | 用于治疗实体癌的her3放射免疫疗法 | |
| AU2021378793B2 (en) | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer | |
| CN111094353A (zh) | 用于癌症的组合治疗 | |
| KR20230005903A (ko) | 항-CD79b 면역접합체를 사용하는 방법 | |
| JP2024519907A (ja) | 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用 | |
| JP2018505144A5 (enExample) | ||
| JP2022513036A (ja) | がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ |